Vaccination against pneumococcal infection in patients with diabetes mellitus

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review highlights the relevance and necessity of vaccination against pneumococcal infection in the post-COVID period. A comparative analysis of vaccination schedules using conjugate and polysaccharide vaccines in patients with diabetes mellitus types 1 and 2 was carried out in accordance with foreign and domestic recommendations.

全文:

受限制的访问

作者简介

A. Tarasova

Privolzhsky Research Medical University

编辑信件的主要联系方式.
Email: taras.al@mail.ru
ORCID iD: 0000-0002-2591-6571

Dr. Sci. (Med.), Professor at the Department of Faculty and Outpatient Pediatrics

俄罗斯联邦, Nizhny Novgorod

M. Kostinov

Mechnikov Research Institute of Vaccines and Serums; Sechenov First Moscow State Medical University

Email: taras.al@mail.ru
ORCID iD: 0000-0002-1382-9403
俄罗斯联邦, Moscow; Moscow

E. Novopoltseva

Privolzhsky Research Medical University

Email: taras.al@mail.ru
ORCID iD: 0000-0001-8492-1509
俄罗斯联邦, Nizhny Novgorod

参考

  1. The top 10 causes of death. URL: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
  2. Redondo Е., Rivero-Calle I., Mascaros E., et al. Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group. Antibiotics (Basel). 2023;12(1):138. doi: 10.3390/antibiotics12010138.
  3. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and etiologies of lower respiratory infections in 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18:1191–210. doi: 10.1016/S1473-3099(18)30310-4.
  4. Lansbury L., Lim B., McKeever T.M., et al. Non-invasive pneumococcal pneumonia due to vaccine serotypes: A systematic review and meta-analysis. eClinicalMedicine. 2022;44:101271. doi: 10.1016/j.eclinm.2022.101271.
  5. Даниленко Е.Д., Цветкова И.А., Никитина Е.В. и др. Характеристика популяции streptococcus pneumoniae, ассоциирующихся с инвазивными пневмококковыми инфекциями в России. VIII Всероссийский конгресс по медицинской микробиологии, клинической микологии и иммунологии (XXVII кашкинские чтения) Тезисы. Проблемы медицинской микологии. 2024;26(2):109. [Danilenko E.D., Tsvetkova I.A., Nikitina E.V. et al. Characteristics of the streptococcus pneumoniae population associated with invasive pneumococcal infections in Russia. VIII All-Russian Congress on Medical Microbiology, Clinical Mycology and Immunology (XXVII Kashkin Readings) Abstracts. Problems of Medical Mycology. 2024;26(2):109. (In Russ.)].
  6. Sempere J., Lamosi M., Lopez Ruiz B., et al. Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004–2020: A national surveillance study. Lancet. Microbe. 2022;3:e744–e752. doi: 10.1016/S2666-5247(22)00127-6.
  7. Cilloniz C., Ewig S., Polverino E., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66:340–6. doi: 10.1136/thx.2010.143982.
  8. Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet. 2022;399:629–55. doi: 10.1016/S0140-6736(21)02724-0.
  9. Immunization agenda 2030: a global strategy to leave no one behind. Vaccine. 2024;42(Suppl. 1):S5–14. doi: 10.1016/j.vaccine.2022.11.042.
  10. Vekemans J., Hasso-Agopsowicz M., Kang G., et al. Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance. Clin Infect Dis. 2021;73(4):e1011–7. doi: 10.1093/cid/ciab062.
  11. Malarski M., Hasso-Agopsowicz M., Soble A., et al. Vaccine impact on antimicrobial resistance to inform Gavi, the vaccine alliance’s 2018 vaccine investment strategy: report from an expert survey. F1000Res. 2019:8:1685. doi: 10.12688/f1000research.20100.1.
  12. Hasso-Agopsowicz M., Sparrow E., Meagan Cameron A., et al. The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens. 2024;42(19, Suppl. 1):S1–8. doi: 10.1016/j.vaccine.2024.06.017.
  13. Im H., Ser J., Sim U., Cho H. Promising expectations for pneumococcal vaccination during covid-19. Vaccines (Basel) 2021;9:1507. doi: 10.3390/vaccines9121507.
  14. Magliano D.J., Harding J.L., Cohen K., et al. Excess Risk of Dying From Infectious Causes in Those with Type 1 and Type 2 Diabetes. Diab Care. 2015;38:1274–80. doi: 10.2337/dc14-2820.
  15. Hodgson K., Morris J., Bridson T., et al. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 2015;144:171–85. doi: 10.1111/imm.12394.
  16. Bader M.S., Yi Y., Abouchehade K., et al. Community-Acquired Pneumonia in Patients with Diabetes Mellitus: Predictors of Complications and Length of Hospital Stay. Am J Med Sci. 2016;352:30–35. doi: 10.1016/j.amjms.2016.02.032.
  17. Беликина Д.В., Малышева Е.С., Петров А.В. и др. COVID-19 при сопутствующем сахарном диабете: особенности клинического течения, метаболизма, воспалительных и коагуляционных нарушений. Современные технологии в медицине. 2020;12(5):6–18. [Belikina D.V., Malysheva E.S., Petrov A.V., et al. COVID-19 in concomitant diabetes mellitus: features of the clinical course, metabolism, inflammatory and coagulation disorders. Modern Technologies in Medicine. 2020;12(5):6–18. (In Russ.)]. doi: 10.17691/stm2020.12.5.01.
  18. Тарасова А.А., Костинов М.П., Мещерякова В.В. и др. Подходы к вакцинации пациентов с сахарным диабетом и ожирением в современной эпидемиологической ситуации. Эпидемиология и вакцинопрофилактика. 2022;21(4):119–24. [Tarasova A.A., Kostinov M.P., Meshcheryakova V.V., et al. Approaches to vaccination of patients with diabetes mellitus and obesity in the current epidemiological situation. Epidemiologia i vakcinoprofilaktika. 2022;21(4):119–24. (In Russ.)]. doi: 10.31631/2073-3046-2022-21-4-119-124.
  19. Костинов А.М., Костинов М.П. Восприимчивость к SARS-CoV-2 привитых против S. pneumoniae – механизмы неспецифического действия пневмококковой вакцины. Педиатрия им. Г.Н. Сперанского. 2020;99(6):183–9. [Kostinov A.M., Kostinov M.P. Susceptibility to SARS-CoV-2 in those vaccinated against S. pneumoniae – mechanisms of non-specific action of the pneumococcal vaccine. Pediatrics journal named after G.N. Speransky. 2020;99(6):183–9. (In Russ.)]. doi: 10.24110/0031-403X-2020-99-6-183-189.
  20. Костинов А.М, Костинов М.П., Машилов К.В. Пневмококковые вакцины и COVID-19 – антагонизм. Медицинский совет. 2020;17:66–73. [Kostinov A.M., Kostinov M.P., Mashilov K.V. Pneumococcal vaccines and COVID-19 – antagonism. Medical Council. 2020;17:66–73. (In Russ.)]. doi: 10.21518/2079-701X-2020-17-66-73.
  21. Зверев В.В., Костинов М.П., Магаршак О.О. и др. Руководство по клинической иммунологии в респираторной медицине. Под ред. М.П. Костинова, А.Г. Чучалина. Изд. 2-е, доп. М., 2018. 302 с. [Zverev V.V., Kostinov M.P., Magarshak O.O., et al. Handbook of Clinical Immunology in Respiratory Medicine. Ed. by M.P. Kostinov, A.G. Chuchalin. 2nd edition, suppl. Moscow, 2018. 302 p. (In Russ.)].
  22. Cilloniz C., Torres A. Diabetes Mellitus and Pneumococcal Pneumonia. Diagnostics 2024;14:859. Doi: 10.3390/ diagnostics14080859.
  23. Kornum J.B., Thomsen R.W., Riis A., et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diab Care. 2008;31:1541–1545. doi: 10.2337/dc08-0138.
  24. Pomar V., de Benito N., Mauri A. et al. Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. BMC Infect Dis. 2020;20:292. doi: 10.1186/s12879-020-05023-5.
  25. Kanyoro C.W., Karoney M., Nyamogoba H., Kamano J. Nasopharyngeal carriage and antibiotic susceptibility of Streptococcus pneumoniae among diabetes patients in western Kenya. Diab Res Clin Pract. 2024;217:111892. doi: 10.1016/j.diabres.2024.111892.
  26. Campling J., Wright H.F., Hall G.C., et al. Hospitalization costs of adult community-acquired pneumonia in England. J Med Econ. 2022;25(1):912–8. doi: 10.1080/13696998.2022.2090734.
  27. Chapman T.J., Olarte L., Dbaibo G., et al. PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children. Expert Rev Vaccines. 2024;23(1):137–47. doi: 10.1080/14760584.2023.2294153.
  28. ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children – United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:1072. doi: 10.15585/mmwr.mm7239a5.
  29. Janssens E., Flamaing J., Vandermeulen C., et al. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value. Acta Clin Belg. 2023;78(1):78–86. doi: 10.1080/17843286.2022.2039865.
  30. Kobayashi M., Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73:793–798. doi: 10.15585/mmwr.mm7336a3.
  31. Коровкин А.С., Обухов Ю.И., Сятчихина Е.Н. Подходы к вакцинации взрослых против пневмококковой инфекции в различных странах мира. Журнал инфектологии. 2024;16(2):5–16. [Korovkin A.S., Obukhov Yu.I., Syatchikhina E.N. Approaches to vaccinating adults against pneumococcal infection in different countries of the world. Zurnal infektologii = Journal Infectology. 2024;16(2):5–16. (In Russ.)]. doi: 10.22625/2072-6732-2024-16-2-5-16.
  32. Morales-Suarez-Varela M., Toledo D., Fernandez-Sierra M.A., et al. A profile of adult severe acute respiratory syndrome coronavirus 2 pneumonia patients according to pneumococcal vaccination status. Vaccines. 2023;11:1630. doi: 10.3390/vaccines11111630.
  33. Koul P.A., Vora A.C., Jindal S.K., et al. Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024). Lung India 2024;41:307–17. doi: 10.4103/lungindia.lungindia_8_24.
  34. Приказ Минздрава России от 06.12.2021 №1122н «Об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок» (Зарегистрировано в Минюсте России 20.12.2021 № 66435). [Order of the Ministry of Health of Russia dated 06.12.2021 No. 1122n «On approval of the national calendar of preventive vaccinations, the calendar of preventive vaccinations for epidemiological indications and the procedure for conducting preventive vaccinations» (Registered with the Ministry of Justice of Russia on 20.12.2021 No. 66435). (In Russ.)].
  35. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. М., 2023. [Algorithms for specialized medical care for patients with diabetes mellitus. Ed. by I.I. Dedov, M.V. Shestakova, A.Yu. 11th issue. M., 2023. (In Russ.)]. doi: 10.14341/DM13042.
  36. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. Пособие для врачей-терапевтов. М., 2019. [Brief algorithms for patient management at the stage of primary health care. Manual for general practitioners. M., 2019. (In Russ.)].
  37. Авдеев С.Н., Алыева М.Х., Баранов А.А. и др. Вакцинопрофилактика пневмококковой инфекции у детей и взрослых. Методические рекомендации. Профилактическая медицина. 2023;26(9–2):3–23. [Avdeev S.N., Alyeva M.Kh., Baranov A.A., et al. Vaccine prevention of pneumococcal infection in children and adults. Guidelines. Preventive medicine. 2023;26(9–2):3–23. (In Russ.)]. doi: 10.17116/profmed2023260923.
  38. Драпкина О.М., Брико Н.И., Костинов М.П. и др. Иммунизация взрослых. Методические рекомендации. М., 2020. 248 с. [Drapkina O.M., Briko N.I., Kostinov M.P. et al. Immunization of adults. Methodological recommendations. M., 2020. 248 p. (In Russ.)].
  39. Shapiro E.D., Berg A.T., Austrian R., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453–60. doi: 10.1056/NEJM199111213252101.
  40. Тарасова А.А., Костинов М.П., Мещерякова В.В. и др. Подходы к вакцинации пациентов с сахарным диабетом и ожирением в современной эпидемиологической ситуации. Эпидемиология и вакцинопрофилактика. 2022;21(4):119–24. [Тarasova A.A., Kostinov M.P., Meshcheryakova V.V., et al. Approaches to vaccination of patients with diabetes mellitus and obesity in the current epidemiological situation. Epidemiologia i vakcinoprofilaktika. 2022;21(4):119–24. (In Russ.)]. doi: 10.31631/2073-3046-2022-21-4-119-124.
  41. Feldman C., Dlamini S., Richards G.A., et al. A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022. J Thorac Dis. 2022;14(10):4150–72. doi: 10.21037/jtd-22-287.
  42. O’Brien K.L., Hochman M., Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet. Infect Dis. 2007;7:597–606. doi: 10.1016/S1473-3099(07)70210-4.
  43. Fletcher M.A., Schmoele-Thoma B., Vojicic J., et al. Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy. Expert Rev Vaccines. 2024;23(1):944–57. doi: 10.1080/14760584.2024.2404636.
  44. Licciardi P.V., Quan Toh Z., Clutterbuck E.A., et al. No Long-Term Evidence of Hyporesponsiveness after Use of Pneumococcal Conjugate Vaccine in Children Previously Immunized with Pneumococcal Polysaccharide Vaccine. J Allergy Clin Immunol. 2016;137:1772–9.e11. doi: 10.1016/j.jaci.2015.12.1303.
  45. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes-2024. Diab Care. 2024;47(Suppl. 1):S52–76. Doi.org/10.2337/dc24-S004.
  46. Yang X., Zhang D., Ou W. Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: A retrospective database analysis. Vaccine. 2018;36:7574–9. doi: 10.1016/j.vaccine.2018.10.
  47. Huijts S.M., van Werkhoven C.H., Bolkenbaas M., et al. Post-hoc analysis of a randomized controlled trial: diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35 (34):4444–9. doi: 10.1016/j.vaccine.2017.01.071.
  48. Silverii G.A., Gabutti G., Tafuri S., et al. Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies. Acta Diabetol. 2024;61(8):1029–39. doi: 10.1007/s00592-024-02282-5.
  49. Рудакова А.В., Брико Н.И., Лобзин Ю.В. и др. Фармакоэкономическая эффективность вакцинации против пневмококковой инфекции пациентов с сахарным диабетом. Эпидемиология и вакцинопрофилактика. 2022;21(5):78–88. [Rudakova A.V., Briko N.I., Lobzin Yu.V. et al. Pharmacoeconomic efficiency of vaccination against pneumococcal infection in patients with diabetes mellitus. Epidemiologia i vakcinoprofilaktika. 2022;21(5):78–88. (In Russ.)]. doi: 10.31631/2073-3046-2022-21-5-78-88.
  50. Koul P.A., Vora A.C., Jindal S.K., Ramasubramanian V. et al. Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP-EXPO Recommendations-2024). Lung India 2024;41:307–17. doi: 10.4103/lungindia.lungindia_8_24.
  51. Du Q-Q., Shi W., Yu D., Yao K.-H. Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines. Hum Vaccin Immunother. 2021;17(12):5628–37. doi: 10.1080/21645515.2021.1985353.
  52. Frost E., Balachandran A., Paulin-Deschenauxc S., et al. The approach of World Health Organization to articulate the role and assure impact of vaccines against antimicrobial resistance. Hum Vaccin Immunother. 2022;18(6):2145069. doi: 10.1080/21645515.2022.2145069.
  53. Sikjær M.G., Pedersen A.A., Wik M.S., et al. Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis. Eur Clin Respir J. 2023;10(1):2168354. doi: 10.1080/20018525.2023.2168354.
  54. Castro J.T., Oliveira G.S., Nishigasako M.A., et al. Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A [J]. PloS One. 2020;15(1):e0228055. doi: 10.1371/journal.pone.0228055.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2024